DURHAM, N.C., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Chimerix (CMRX, Financial), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that company management will participate in upcoming investor conferences in September. Conference details are as follows:
- Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix will present at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 8:45 a.m. ET in New York City.
A live audio webcast of Dr. Nichols’ presentation at the H.C. Wainwright Global Investment Conference will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
In addition, Chimerix will be represented at the following conferences
- Citi 13th Annual Biotech Conference on Wednesday September 5, 2018 in Boston, and,
- Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018 in New York City.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
(212) 362-1200
Media:
Laurie Masonson
W2O Group
[email protected]
(917) 459-6164
